Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

UnitedHealth Group Inc (NYSE:UNH)

• Dividend Yield: 3.02%
• Mizuho analyst Ann Hynes maintained an Outperform rating and cut the price target from $430 to $350 on Feb. 5, 2026. This analyst has an accuracy rate of 69%.
• Truist Securities analyst David Macdonald maintained a Buy rating and cut the price target from $410 to $370 on Feb. 2, 2026. This analyst has an accuracy rate of 67%
• Recent News: On Jan. 27, the company reported adjusted earnings of $2.11, down from $6.81 a year ago, beating the consensus of $2.10.
• Benzinga Pro’s real-time newsfeed alerted to latest UNH news.

Viatris Inc (NASDAQ:VTRS)

• Dividend Yield: 3.04%
• Piper Sandler analyst David Amsellem maintained a Neutral rating and raised the price target from $9 to $12 on Jan. 28, 2026. This analyst has an accuracy rate of 78%.
• Barclays analyst Glen Santangelo initiated coverage on the stock with an Overweight rating and a price target of $15 on Dec. 9, 2025. This analyst has an accuracy rate of 55%
• Recent News: Viatris said it will report fourth quarter financial results on Feb. 26.
• Benzinga Pro's real-time newsfeed alerted to latest VTRS news

CVS Health Corp (NYSE:CVS)

• Dividend Yield: 3.39%
• B of A Securities analyst Michael Cherny maintained a Buy rating and cut the price target from $100 to $95 on Jan. 27, 2026. This analyst has an accuracy rate of 70%.
• JP Morgan analyst Lisa Gill maintained an Overweight rating and raised the price target from $93 to $101 on Dec. 17, 2025. This analyst has an accuracy rate of 54%.
• Recent News: On Feb. 10, CVS Health reported upbeat earnings for the fourth quarter.
• Benzinga Pro’s real-time newsfeed alerted to latest CVS news

Photo via Shutterstock